Lantheus (NASDAQ:LNTH) Shares Down 5.5% – Here’s Why

Lantheus Holdings, Inc. (NASDAQ:LNTH) was down 5.5% during trading on Tuesday . The stock traded as low as $92.55 and last traded at $92.90. Approximately 141,442 shares traded hands during trading, a decline of 79% from the average daily volume of 673,070 shares. The stock had previously closed at $98.31.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Truist Financial reissued a “buy” rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. The Goldman Sachs Group began coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target for the company. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, JMP Securities restated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.86.

Lantheus Stock Performance

The company’s 50-day simple moving average is $91.90 and its two-hundred day simple moving average is $100.07. The firm has a market cap of $6.43 billion, a PE ratio of 15.40 and a beta of 0.46.

Insiders Place Their Bets

In other news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 1.50% of the company’s stock.

Institutional Trading of Lantheus

A number of hedge funds have recently modified their holdings of LNTH. Wilmington Savings Fund Society FSB purchased a new position in Lantheus during the 3rd quarter valued at about $25,000. Signaturefd LLC lifted its holdings in shares of Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 92 shares during the last quarter. UMB Bank n.a. boosted its position in shares of Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares in the last quarter. Kathleen S. Wright Associates Inc. purchased a new stake in shares of Lantheus in the 3rd quarter worth approximately $51,000. Finally, GAMMA Investing LLC increased its position in Lantheus by 45.5% during the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after buying an additional 146 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.